Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Eur J Paediatr Neurol ; 15(2): 171-3, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20609603

ABSTRACT

BACKGROUND: We report a boy with an unusually late presentation of Farber lipogranulomatosis type l. CASE STUDY: The first symptoms appeared at the end of the first year of life in the form of joint swelling; other symptoms such as cherry-red spot, hoarseness, subcutaneous nodules appeared much later. The history of the disease, from the first symptoms till his early death, lasted 26.5 months. The neuronal dysfunction accompanied by the rapid neurological deterioration with seizures and myoclonias, rather than the general dystrophy, seemed to limit the duration of disease in our patient and provoked his early death. Diagnosis was confirmed by analysis of ceramide metabolism in cultured fibroblasts and of the ASAH1 gene, which indicated homozygosity for a novel point mutation. CONCLUSION: The deficient activity of acid ceramidase correlated well with poor prognosis of the disease in our boy, in contrast to late appearance of dermal nodules and the subsequent severe clinical course with fatal outcome. Farber lipogranulomatosis should be suspected in children with joint swelling as the first and only symptom of disease. In order to advance our knowledge towards establishing genotype-phenotype correlations in Farber's disease, detailed analysis of the ASAH1 gene is needed.


Subject(s)
Acid Ceramidase/genetics , Farber Lipogranulomatosis/genetics , Genetic Predisposition to Disease/genetics , Mutation/genetics , Age of Onset , Child, Preschool , Croatia/ethnology , Farber Lipogranulomatosis/pathology , Fatal Outcome , Humans , Male
2.
Acta Neurol Scand ; 116(6): 361-7, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17986093

ABSTRACT

OBJECTIVES: To investigate the prevalence of active epilepsy in Croatia. MATERIAL AND METHODS: Patient data collected by means of questionnaires completed by primary healthcare physicians; epilepsy was previously confirmed in the patients by neurologists or neuropaediatricans. RESULTS: One hundred and twenty-seven of 180 (71%) physicians provided the requested information. The total sample was 212 069 people and of these 1022 had active epilepsy. Prevalence rates (per 1000) for the following age-groups were: age 0-7: 3.5; age 8-18: 6.4; age 19-45: 5.0; age 46-65: 4.7; age >65: 4.4. The age-adjusted prevalence rates for the standard populations were 4.9/1000 (European population) and 5.0/1000 (WHO world population). Fifty-one physicians (29%) stated only the number of patients they considered as having active epilepsy but without the requested details. If their patients were also included, the estimated crude prevalence rate would be 5.5/1000. CONCLUSIONS: It is likely that the prevalence of active epilepsy in Croatia is between 4.8 and 5.5/1000; this is in keeping with findings from other European countries.


Subject(s)
Epilepsy/epidemiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Anticonvulsants/therapeutic use , Child , Child, Preschool , Cognition Disorders/epidemiology , Cohort Studies , Comorbidity , Croatia/epidemiology , Data Collection , Epilepsy/diagnosis , Female , Geography , Humans , Intellectual Disability/epidemiology , Male , Middle Aged , Prevalence
4.
Pediatr Res ; 28(3): 247-55, 1990 Sep.
Article in English | MEDLINE | ID: mdl-2235122

ABSTRACT

Evidence is emerging that primary systemic carnitine deficiency, a potentially lethal but eminently treatable inborn error of fatty acid oxidation, involves a cellular defect in the uptake of carnitine. We present four unrelated children with primary carnitine-responsive cardiomyopathy, weakness (with or without hypoketotic hypoglycemic encephalopathy), low serum and/or tissue carnitine concentrations, and severe renal carnitine leak. Dicarboxylic acids were absent in the urine of three children who were tested, and all four had a rapid and dramatic improvement in cardiac function, strength, and somatic growth after carnitine therapy. We studied carnitine uptake in cultured skin fibroblasts from all four children and seven of the eight healthy nonconsanguinous parents. [3H]L-carnitine uptake was evaluated in vitro under linear time kinetics. Substrate concentrations were varied from 0.1 to 1000 microM. Physiologic uptake was determined at carnitine concentrations between 0.1 and 50 microM. Nonspecific uptake was determined at a concentration of 10 mM. The four patients had negligible uptake throughout the physiologic range, implying a marked deficiency in the specific high-affinity, low-concentration, carrier-mediated uptake mechanism. At a concentration of 5 mumol/L, the mean velocity of uptake in the four patients was 2% of control values. Their parents showed intermediate maximal rates of carnitine uptake ranging from 13 to 44% of control Vmax values, but normal Km values, suggesting that the heterozygotes had a reduced number of normal functioning carnitine transporters. The observed reduction in Vmax values for the parents supports an autosomal recessive inheritance pattern and may be a more sensitive indicator of heterozygosity than serum carnitine concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Cardiomyopathies/metabolism , Carnitine/deficiency , Lipid Metabolism, Inborn Errors/metabolism , Biological Transport, Active , Cardiomyopathies/drug therapy , Cardiomyopathies/etiology , Carnitine/metabolism , Carnitine/therapeutic use , Child , Child, Preschool , Fatty Acids/metabolism , Female , Fibroblasts/metabolism , Humans , Lipid Metabolism, Inborn Errors/complications , Lipid Metabolism, Inborn Errors/drug therapy , Male , Skin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...